Jirgin Tsaro na Tsaro CAS 1156491-10-9 (1R,2S) -rel-2- (3,4-Difluorophenyl) cyclopropanamine hydrochloride Mafi kyawun inganci mafi ƙarancin farashi

Ticagrelor magani ne na baki, sunan sa na Amurka Brilinta, kuma sunan sa na Turai Brilique. Ticagrelor wani antagonist mai karɓar platelet adenosine diphosphate (ADP) ne mai jujjuyawa wanda aka tsara don hana platelet daga mannewa tare da samar da gudan jini wanda zai iya haifar da bugun zuciya da bugun jini. A cikin Amurka, FDA ta fara amincewa da ticagrelor a cikin Yuli 2011 don kula da tsofaffi marasa lafiya tare da ciwo mai tsanani (ACS). Bayanan asibiti sun nuna cewa ticagrelor yana da tasiri sosai fiye da clopidogrel wajen rage mutuwar zuciya da jijiyoyin jini don akalla watanni 12 bayan wani taron ACS. Bugu da ƙari, ticagrelorChemicalbook kuma ya rage yawan ƙwayar thrombosis na stent (ST) a cikin marasa lafiya da suka karbi stent don kula da ACS. A cikin watan Yuni 2020, AstraZeneca ta ba da sanarwar cewa Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da maganin Brilinta (ticagrelor) don amfani da marasa lafiya da ke da haɗarin cututtukan jijiyoyin jini (CAD) don rage haɗarin bugun zuciya na farko. ko hadarin bugun jini. A cikin Nuwamba 2020, AstraZeneca ta ba da sanarwar cewa Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da sabon nuni ga anticoagulant Brilinta (ticagrelor), tare da aspirin, don maganin ischemia mai tsanani. A cikin marasa lafiya masu fama da bugun jini ko babban haɗari na wucin gadi na ischemic (TIA), yana rage haɗarin bugun jini na gaba.